Abstract:Aminoglycosides are important broad-spectrum antibiotics used in the therapy of many microbial infections. As the bacterial resistance to antibiotic therapy is appearing as an increasingly significant threat to public health, the development of aminoglycoside antibiotics with extended antibacterial spectrum and potency, devoid of nephro- and ototoxicity, and evading the resistance process returns to the focus of researchers. In this review, various developments brought to the aminoglycoside family of antibiotics effective against resistant bacteria have been described, focused on chemical modifications, drug-modifying enzyme inhibitors, and conformationally constrained analogs, as well as related antibacterial compounds, with the hope to provide information useful in rational design of novel antibiotics addressing bacterial resistance, and paving the way for new perspectives in antimicrobial therapy. Keywords: Aminoglycoside antibiotics, drug-modifying enzymes, bacterial resistance, inhibitor, antimicrobial activity, Aminoglycoside, broad-spectrum antibiotics, antimicrobial therapy, Gram-negative, Gram-positive, aminocyclitol, glycosidic linkage, 2-deoxystreptamine, streptidine ring, spectinomycin, Mycobacterium tuberculosis, neomycin, pa-ramomycin, kanamycins, tobramycin, gentamicins, semi-synthetic derivatives amikamycin, dibekacin, sisomicin, netilmicin, Ototoxicity, 16S rRNA, phosphotransferases, adenyltransferases, acetyltrans-ferases, Anti-APH(3')s, Aminoglycoside 3'-phosphotransferases, Gram-negative APH(3'), neomycin B, anti-anthrax drugs, Anti-APH(2'')/AAC(6'), methicillin-resistant Staphylococcus aureus, O-acetyltransfer, N-acetyltransfer, Arbekacin, aminoglycoside-modifying, 5-deoxy-5-episubstituted arbekacin derivatives, 5-deoxy-5-epiamino-ABK, aminoglycoside-modifying enzyme, resistance nodulation division, tetraazidoneamine, ribostamycin and pyranmycin, pSF815 plasmid, acetyl coenzyme A, synthetic AAC(6') in-hibitors, pyrophosphate group, structure-activity relationships, ANT (2'') Inhibitors, aminoglycoside-resistant bacteria, APH Inhibitors, nucleophilic amino acid side chain, protein kinases, acetyltransferases, nucleo-tidyltransferases, sulfotransferases, X-ray crystallography, paromomycin, Dimeric Derivatives, hydroxyamine motif, Hoog-steen face, neamine dimers, vancomycin-resistant enterococci, fluoroquinolone- ciprofloxacin, DNA gyrase, topoisomerase, Cipro-NeoB hybrids, C16 or C20 fatty acid, multidrug resistant, 3,5-diamino-piperidinyl triazines, Neamine-derived pseudodisaccharides, Non-Carbohydrate Inhibitors of AGMEs, bovine antimicrobial peptide indolicidin

Antibiotic GP, a new aminoglycoside antibiotic complex produced by Micromonospora echinospora mutant 129-P1, which can tolerate higher concentrations of phosphate

Isolation and Partial Characterization of Antibiotics Produced by Paenibacillus Elgii B69.

Glycodiversification of gentamicins through in vivo glycosyltransferase swapping enabled the creation of novel hybrid aminoglycoside antibiotics with potent activity and low ototoxicity

Antibiotic synergist OM19r reverses aminoglycoside resistance in multidrug-resistant Escherichia coli

Complete reconstitution of the diverse pathways of gentamicin B biosynthesis

Assembly of a novel biosynthetic pathway for gentamicin B production in Micromonospora echinospora

Battacin (octapeptin B5), A New Cyclic Lipopeptide Antibiotic from Paenibacillus Tianmuensis Active Against Multidrug-Resistant Gram-Negative Bacteria

Recent advances in the biosynthesis and production optimization of gentamicin: A critical review

Engineering the methyltransferase through inactivation of the genK and genL leads to a significant increase of gentamicin C1a production in an industrial strain of Micromonospora echinospora 49-92S

Potent synergy and sustained bactericidal activity of polymyxins combined with Gram-positive only class of antibiotics versus four Gram-negative bacteria

Polymyxin B-Polysaccharide Polyion Nanocomplex with Improved Biocompatibility and Unaffected Antibacterial Activity for Acute Lung Infection Management

Development of Aminoglycoside Antibiotics Effective Against Resistant Bacterial Strains

Polymyxin B in Combination with Glycerol Monolaurate Exerts Synergistic Killing against Gram-Negative Pathogens

Altering glycopeptide antibiotic biosynthesis through mutasynthesis allows incorporation of fluorinated phenylglycine residues

Potent Antibacterial Nanoparticles against Biofilm and Intracellular Bacteria

Design, Synthesis and Activity Evaluation Against Drug‐Resistant Bacteria of 6'‐Amidine Modified Aminoglycoside Derivatives

Polymyxin B nonapeptide potentiates the eradication of Gram-negative bacterial persisters

Synthesis of peptidomimetics as antibiotic adjuvants for combination with aztreonam to combat MDR Pseudomonas aeruginosa

Antibiotic resistance and inhibition mechanism of novel aminoglycoside phosphotransferase APH(5) from B. subtilis subsp. subtilis strain RK

The effect of combinations of a glyphosate-based herbicide with various clinically used antibiotics on phenotypic traits of Gram-negative species from the ESKAPEE group

A cyclic adenosine monophosphate response element-binding protein inhibitor enhances the antibacterial activity of polymyxin B by inhibiting the ATP hydrolyzation activity of CrrB